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Abstract
Background: The diagnostic value of CSF tau for Creutzfeldt-Jakob disease (CJD) has been widely evaluated, showing a
markedly disease-relative manner. However, the profiles of tau isoforms in CSF of CJD patients remain unknown. Here, we
prepared the exon-specific antibodies against the peptides encoded by exon-2, exon-3 and exon-10 of human tau protein
and evaluated the reactive profiles of tau in CSF samples from the patients with probable CJD.
Methodology/Principal Findings: Sequences encoding exon-2, exon-3 and exon-10 of human tau protein were cloned into
a prokaryotic expression vector pGEX-2T. Using recombinant fusion proteins GST-E2, GST-E3 and GST-E10, three tau exon-
specific antibodies were elicited. Reliable specificities of the prepared antibodies were obtained after a serial of purification
processes, not only in recognizing the tau peptides encoded by exon-2, -3 and -10, but also in distinguishing six
recombinant tau isoforms by Western blot and ELISA. Three predominant tau-specific bands were observed in CSF samples
with the exon-specific and the commercial tau antibodies, respectively, showing different reactive profiles between the
groups of probable CJD and non-CJD. A 65 KD band was detected only in the CSF samples from probable CJD patients,
especially with the antibodies against exon-2 (Anti-tE2) and exon-10 (Anit-tE10). The appearances of 65 KD band in CSF
correlated well with positive 14-3-3 in CSF and typical abnormality in EEG. Such band was not observed in the CSF samples
of six tested genetic CJD patients.
Conclusions/Significance: Three exon-specific polyclonal antibodies were successfully prepared. Based on these antibodies,
different CSF tau profiles in Western blots were observed between the groups of probable CJD and non-CJD. A disease-
specific tau band emerged in the CSF samples from probable sporadic CJD, which may supply a new biomarker for
screening sporadic CJD.
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Introduction
Creutzfeldt-Jakob disease (CJD) is a rapidly progressive and
ultimately fatal disorder of the central nervous system believed to
be caused by prion [1]. The clinical syndrome of CJD include
rapidly progressive dementia, myoclonus, visual or cerebellar
symptoms, pyramidal or extrapyramidal signs and akinetic mutism
[2]. To date, a definite diagnosis can only be made by
neuropathological examination and demonstration of the patho-
logical isoform of the prion protein (PrP
Sc) in central nervous
tissues, either at biopsy or autopsy [3]. In the patients with new-
variant CJD (vCJD), a pathologic isoform was also detected in
tonsils [4]. Probable or possible diagnosis of CJD, especially
sporadic CJD (sCJD), can be intravitally achieved according to
clinical manifestations, typical changes in EEG and the appear-
ance or alternation of some neuronal proteins in cerebrospinal
fluid (CSF) [5]. However, only immunoblot for CSF 14-3-3 is
included in the diagnostic criteria [6,7], despite the fact that
the other surrogate markers also may have a high differential
diagnostic potential [8].
Tau is a microtubule-associated protein capable of promoting
microtubule assembly and stability in the nervous system. In brains
from normal human adults, six isoforms of tau have been reported,
which are encoded from a single gene with 16 exons by alternative
mRNA splicing [9]. They differ from one another by the presence
or absence of a 29-amino acid insertion (encoded by exon-2) or 58-
amino acid insertion (encoded by exon-2 and -3) in the amino-
terminal half of the protein, as well as by presence or absence of a
31-amino acid repeat (encoded by exon-10) in its carboxyl-
terminal half. Based on the constitution of exon-2, -3 or -10 in tau,
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Tau381, Tau383, Tau410, Tau412 and Tau441. All tau isoforms
contain other three common repeats in its C-terminal half, which
are responsible for interacting with microtubule. Therefore,
according to the repeat of exon-10 in C-terminal peptide, tau
proteins can be divided into two groups, 3R-tau and 4R-tau.
Based on the presence of the insertion(s) of exon-2 and/or exon-3
in N-terminus, tau proteins have three forms, namely 1N-tau, 2N-
tau and 0N-tau [10,11]. The presences of tau isoforms in human
brains may vary with the age, i.e. the amounts of 3R-tau and 4R-
tau are comparable in adult cerebral cortex, while 0N-tau is
predominant in the developing brains [12].
Under some pathological conditions, tau protein has become
the major component of the intracellular filamentous deposits,
such as Alzheimer’s disease (AD). Altered proportions of tau
isoforms have been observed in frontotemporal dementia,
Parkinsonism linked to chromosome 17 (FTDP-17) and Pick
disease [11]. Promising results of the diagnostic sensitivity and
specificity of tau-protein in CSF with ELISA have been reported,
which has been accepted as a standard procedure in AD diagnosis
and evaluation of therapy [13]. The diagnostic value of CSF tau
for CJD has been widely evaluated, showing a markedly disease-
relative manner [14]. However, the profiles of tau isoforms in CSF
of CJD patients remain unknown, possibly due to lacking of tau
isoform- or exon-specific antibodies.
In this study, human tau exon-2, -3 and -10 specific fusion
proteins and various tau isoform proteins were individually
expressed in E. coli, Using tau exon-2, -3 and -10 fusion proteins
as antigens, tau exon-specific polyclonal antibodies were prepared.
We confirmed that the prepared antibodies recognize and
distinguish tau isoforms containing various modules of exon.
Based on the prepared polyclonal antibodies, the tau profiles in
CSF samples from 96 Chinese patients with probable sporadic
CJD, 6 genetic CJD and 22 cases who were excluded the
possibility of CJD were analyzed by Western blots. A 65 KD tau-
specific band, which was recognized mostly by the antibodies
against tau Exon-2 and-10, emerged specifically in a large portion
of CSF samples of probable sporadic CJD patients. Our study
provide the reliable human tau exon-specific polyclonal antibodies
and the 65 KD tau-specific band may be used as a new biomarker
for screening sporadic CJD.
Materials and Methods
Ethics statement
Usage of the stored human clinical samples in this study, which
was one of the important clinical materials in China CJD
Surveillance System, has been approved by the Ethical
Committee of National Institute for Viral Disease Prevention
and Control, China CDC. All signed informed consents have
been collected and stored by the China CJD Surveillance Centre.
Animal experiment in this study was approved by the
Experimental Ethical Committee of National Institute for Viral
Disease Prevention and Control, China CDC. All mice and
rabbits were maintained under clean grade. Housing and exper-
imental protocols were in accordance with the Chinese Regu-
lations for the Administration of Affairs Concerning Experimen-
tal Animals.
Plasmid construction
The exon-2, -3 and -10 cDNAs of human tau were obtained
from human peripheral blood monocytes DNA by PCR. Primers
for exon-2, -3 and -10 were synthesized based on the human tau
cDNA sequences released on GenBank (NM_005910.4), with a
Bam HIo rEcoRI restriction enzyme site at the 59-terminus,
respectively (Table 1). To construct different human tau isoforms,
overlapping PCR was performed using pET-17b-tau441 [15] or
pGEX-2T-tau352 [16] as the templates. The primers used in
overlapping PCR contained a Bam HIs i t ei nt h ef o r w a r dp r i m e r s
and a KpnI site in the reverse primers. PCR amplification was
performed at the condition of denaturing at 94uCf o r3 0s e c ,
annealing at 55uC for 30 sec, extending at 72uC for 1 min, totally
30 cycles. Briefly, to construct human tau isoforms with 381 and
410 amino acids, two PCR amplifications were conducted with
the primer mixture of TauN and E2-down, or E3-down, using
pET-17b-Tau441 as the template, as well as the mixture of
LE2-352 or LE3-352 and TauC, using pGEX-2T-Tau352 as the
template. After purification, two PCR products were annealed
and the full-length sequences of tau381 and tau410 were
amplified with primer TauN and TauC. To construct tau isoform
with 383 amino acids, two PCR amplifications were conducted
with the primer mixture of TauN and LE10-352, using pGEX-2T-
Tau352 as the template, as well as the mixture of E10-up and
TauC, using pET-17b-Tau441 as the template. After purification,
two PCR products were annealed and the full-length sequence of
tau383 was amplified with primer TauN and TauC. To construct
tau isoform with 412 amino acids, two PCR amplifications were
conducted with the primer mixture of TauN and E2-down, using
pET-17b-Tau441 as the template, as well as the mixture of LE2-
352 and TauC, using pET-17b-Tau383 as the template. After
purfication, two PCR products were annealed and the full-length
sequence of tau412 was amplified with primer TauN and TauC.
The four human tau isoforms were cloned into plasmid pMD18-
T. After sequence verification, various isoform sequences were
released from cloning vectors pET-17b-Tau441 or pGEX-2T-
Tau352 and subcloned into pQE30 vector, generating prokary-
otic expression recombinant plasmids pQE30-tau352, pQE30-
tau381, pQE30-tau383, pQE30-tau410, pQE30-tau412 and
pQE30-tau441.
Table 1. The primers used for the constructions of various
recombinant plasmids.
Name Sequences (from 59 to 39) Enzyme
tau2-up GGATCCGCACCCATGGCAGAAGGAGGAG BamH1
tau2-down GAATTCTCACCGCCTCGGCTTGTCACAT EcoRI
tau3-up GGATCCGCACCCATGGCAGAAGGAGGAG BamHI
tau3-down GAATTCTCACCGCCTCGGCTTGTCACAT EcoRI
tau10-up GGATCCGCACCCATGGCAGAAGGAGGAG BamHI
tau10-down GAATTCTCACCGCCTCGGCTTGTCACAT EcoRI
TauN CGGGATCCATGGCTGAGCCCCG BamHI
E2-down TTCCGCTGTTGGAGTGCTCTTAG No
E3-down TGTGGTTCCTTCTGGGATCT No
L1-E10 AAGATCCAGCTTCTTATTAATTATCTGCACCTT
CCCGCCTCCCGGCTGGTGCTTCAGG
No
TauC GGGGTACCTCACAAACCCTGCTTG Kpn I
LE2-352 AGCACTCCAACAGCGGAAGCTGAAGAAGCA
GGCATTGGAGACA
No
LE3-352 ATCCCAGAAGGAACCACAGCTGAAGAAGCA
GGCATTG
No
E10-up GTGCAGATAATTAATAAGAAGCTGGAT No
doi:10.1371/journal.pone.0011886.t001
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The recombinant prokaryotic proteins tagged with GST were
bacterially expressed in E. coli BL21(DE3) and purified with
Glutathione Sepharose 4B (GE Healthcare, USA) according to the
protocol described in our previous study [17]. The recombinant
prokaryotic proteins tagged with six histidines were bacterially
expressed in E. coli M15 and purified with affinity chromatography
of Ni-NTA agarose (GE Healthcare, USA) according to the
protocol described elsewhere [18]. Briefly, the bacteria trans-
formed with individual expressing plasmids were grown to an
OD600 of 0.5–0.6 and induced with isopropyl-D-thiogalactoside
(IPTG) at a final concentration of 1 mM. Cells were harvested by
centrifugation and resuspended in 0.01 M PBS, pH 7.4, with
1 mM phenylmethylsulfonyl fluoride (PMSF) as a protease
inhibitor. Lysozyme was added to a final concentration of
2 mg/ml, and cells were lysed by incubation for 30 min and
treated with sonication 24 times with power of 400 W at 10 s
intervals. To obtain purified proteins, the soluble cell lysate was
incubated with Glutathione Sepharose 4B or nickel-NTA agarose
and stirred at 4uC overnight. Fusion proteins were eluted
according to the manufacturer’s protocols. The purities of the
purified proteins were verified by SDS-PAGE. The specificity of
the purified fusion proteins were evaluated by Western blotting
with the anti-GST mAb (Tiangen Tech, China).
Preparation and purification of mouse and rabbit
anti-GST-E2, E3, E10 antisera
Antibodies against exon-2 and exon-3 of human tau were raised
in rabbits and that against exon-10 was raised in mice using the
purified GST-E2, GST-E3 and GST-E10 fusion proteins as
antigens. Briefly, the rabbits and mice were subcutaneously
injected respectively with 0.8 mg and 0.1 mg antigens mixed with
an equal volume of Freund’s complete adjuvant. Two weeks later,
0.5 mg and 0.08 mg antigen mixed with an equal volume of
Freund’s incomplete adjuvant were subcutaneously given, respec-
tively, for a total of four-time immunizations. Three days after the
last injection, the blood was taken from the carotid artery of
rabbits and the hearts of mice. The whole IgG from rabbits and
mice were purified by Protein A/G following the manufacturer’s
instructions (Sigma, USA/GE Healthcare, USA), respectively.
Purification of human tau exon-specific antibodies
To prepare human tau exon-specific antibodies, CNBr-
activated Sepharose 4B (GE Healthcare, USA) coupled with
GST protein was prepared. 5 mg GST protein was dissolved in
the coupling buffer (0.5 M NaCl, 0.1 M NaHCO3, pH 8.3).
0.3 mg freeze-dried powder of CNBr-activated Sepharose 4B was
swelled and washed with 1 mM HCl (pH 2.5) in order to wash
away the additives and preserve the activity of the reactive group,
which otherwise hydrolyzed at high pH. Rotating the mixture end-
over-end at room temperature for 1 h or at 4uC overnight. After
washing away excess GST protein with 5 volumes of coupling
buffer, the mixture was transferred to 0.1 M Tris-HCl buffer,
pH 8.0 and incubated at room temperature for 2 h. The mixture
was subsequently washed with at least three cycles of the buffers
with alternating pH values. Each cycle consisted of a wash with
0.1 M acetate buffer, pH 4.0 containing 0.5 M NaCl followed by
a wash with 0.1 M Tris-HCl, pH 8.0 containing 0.5 M NaCl. To
remove the anti-GST component from the prepared antisera, the
whole IgG from rabbits or mice were mixed with CNBr-GST
agarose at the ratio of 1:4 and incubated at 4uC overnight. The
mixtures were centrifuged at 450 g for 3 min and the supernatant
was collected as the purified GST-free antibody.
ELISA
To test the specificity and sensitivity of purified human tau
exon-specific antibodies, an indirect ELISA was established.
Briefly, various GST-tau fusion proteins as well as GST protein
were dilute to a final concentration of 2 mg/ml in PBS and coated
onto 96-well ELISA plates. After blocking with 200 ml 1% BSA in
PBST (phosphate buffered saline, pH 7.6, containing 0.05%
Tween-20), 100 ml of prepared antibodies gradient diluted in
blocking buffer were added and incubated at 37uC for 2 h. The
plates were washed with PBST for three times and 100 mlo f
1:15000-diluted HRP-conjugated secondary antibody were sub-
jected into each well at 37uC for 2 h. Bound antibody was detected
using 3, 39,5 ,5 9-tetramethylbenzidine (TMB) (Sigma, USA).
Absorbance was measured at 450 nm after terminating the
reaction by addition of 2 M H2SO4. The titration of the purified
antibodies was evaluated following the rule that positive limit is
determined as P/N value$2.1.
Clinical samples
Totally 96 CSF samples from the patients diagnosed as
‘‘probable CJD’’, 6 samples from the patients of ‘‘genetic or
familial CJD’’ and 22 samples from the patients who were not
fulfill with criteria for probable or possible CJD as the control
subjects were included for this study. All patients were referred by
the China CJD Surveillance Centre and the diagnoses of CJD
were made according to WHO CJD diagnostic criteria. The
criteria were described as following. Probable CJD: Patients with a
rapidly progressive dementia of less than 2 years’ duration,
periodic sharp-wave complexes in the EEG or a positive test for
14-3-3 protein, and two of the following: myoclonus, visual or
cerebellar symptoms, pyramidal or extrapyramidal signs and
akinetic mutism. Possible CJD: Patients fulfilling the preceding
criteria but without typical EEG abnormalities or a positive test for
14-3-3 protein. CSF samples were obtained by standard clinical
procedures and were free of blood contamination.
The median ages at onset of the probable CJD and control
patients were 60- (range: 33–76) and 58-year-old (range: 43–88),
respectively. No age and gender differences were observed
between probable CJD and control patients. Typical periodic
sharp-wave complexes in EEG were observed in 57 out of 59
(94.9%) probable CJD patients, and in 2 out of 10 (20%) control
patients, having significantly higher EEG positive rate than control
(P,0.01). The positive rates of CSF 14-3-3 in probable CJD cases
and control were 80.2% and 45.5%, with significant difference
(P,0.01). Most patients were Met/Met in PRNP codon 129,
except one Met/Val in one probable CJD and one in control. The
main features of the probable CJD and control cases were
summarized in Table 2.
Additionally, CSF samples from six gCJD patients were enrolled
in this study. They were one G200K (age: 63 y), one T188K (age:
58 y), two G114V (age: 45 and 26 y) familial CJDs (fCJD), one
P102L Gestermann-Strauss-Shenken Syndrome (GSS, age: 58 y)
and one D178N fatal familial insomnia (FFI, age: 24 y).
Western blots
The recombinant fusion protein GST-E2, GST-E3 and GST-
E10 were separated in 15% SDS-PAGE, the recombinant tau
isoforms and human CSF samples were separated in 10% SDS-
PAGE, respectively. After electro-transferred onto PVDF mem-
branes (Millipore, USA) using a semi-dry blotting system (Bio-Rad,
USA), the membranes were blocked with 1% BSA in PBST at 4uC
overnight. Tau specific signals were detected with 1:5000 mAb
Anti-Tau-1 (Millipore, USA), 1:1000 rabbit-derived tau exon-
specific antibody or 1:500 mouse-derived tau exon-specific
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(HRP)-conjugated anti-mouse or anti-rabbit IgG (Thermo, USA).
The reactive signals were visualized by ECL kit (PE Applied
Biosystems, USA). The image of immunoblot was scanned with
Typhoon (GE Healthcare, USA) and digitalized, and saved as TIF
format. The protein bands were quantified by densitometry using
computer-assisted software Image TotalTech (GE Healthcare,
USA).
MALDI-ToF
Sample preparation for mass spectrometry was performed
automatically in Ettan Spot Handling Workstation according to
the manufacturer’s protocol. The purified fusion proteins were
mixed with matrix solution (15 mg/ml sinapic acid) and dotted on
the targeting areas. After Drying, the samples were desalted with
0.1% trifluoroacetic acid. Samples were analyzed in a time-of-
flight mass spectrometer (Ettan MALDI-ToF Pro, GE Healthcare,
USA) and the signals were collected with the Ettan MALDI-ToF
Pro software system.
Statistical analysis
The data were processed with SPSS16.0 statistics software,
descriptive data were expressed as median (range) for continuous
variables and as percent (%) for categorical variables. Character-
istic bands’ relative gray levels were tested for normal distribution
using Shapiro-Wilk test. Analysis of continuous variables was done
using the rank sum test (for two groups, Mann-Whitney U test).
Spearman’s Correlation test was used to test a linear correlation
between positive rate of characteristic bands and that of 14-3-3 or
EEG. Categorical variables were compared using the Chi-Square
test.
Results
Preparation of human tau exon-specific antibodies
With a PCR protocol, the sequences encoding human tau exon-
2, -3 and -10 were amplified, which were 87-, 87- and 93-bp long,
respectively (data not shown). The PCR products were individu-
ally cloned into a prokaryotic expression vector pGEX-2T and the
recombinant fusion proteins were expressed in soluble form and
purified using affinity chromatography of Glutathione Sepharose
4B. SDS-PAGE gel revealed a single protein band around 30 KD
in each preparation (Fig. 1A). Quantitative analyses of the gray
values of all signals in each lane illustrated that the purities of
GST-E2, GST-E3 and GST-E10 were approximately 88%, 84%,
and 83%, respectively. Mass spectrometry assays revealed that the
molecular weights of the purified GST-E2, GST-E3 and GST-E10
were 29719.319-, 29765.973- and 29780.629-Dalton (supplemen-
tal Fig. S1). Western blot analyses with GST-specific mAb
identified a specific reactive band at the expected position in each
preparation (Fig. 1B).
To prepare the specific antibody against different human tau
exons, experimental rabbits and mice were immunized with the
purified GST-E2, GST-E3 and GST-E10. The antisera were
further purified with protein A/G purification and CNBr-GST
agarose. To test the specificities of the prepared human tau exon-
specific antibodies, the recombinant proteins GST-E2, GST-E3,
GST-E10 and GST were employed into SDS-PAGE and reacted
with the various prepared and commercial antibodies in Western
blots. Fig. 1C confirmed that all the prepared rabbit-derived
antibodies against tau exon-2 (Anti-tE2) and -3 (Anti-tE3), mouse-
derived antibody against tau exon-10 (Anti-tE10) recognized only
the corresponding immunogen, but not the other tau-exon fusion
proteins or GST protein.
To test the sensitivity of human tau exon-specific antibodies, an
indirect ELISA was carried out and equal amounts of the purified
antigen or GST protein were coated on the plate. The results
illustrated that the purified tau exon-specific antibodies induced
very low cross-reaction with GST protein, even in the preparations
with highly concentrated antiserum (Fig. 1D). With the rule of P/N
value$2.1, the titers of antibodies Anti-tE2, Anti-tE3 and Anti-
tE10 reached to 1:480000, 1:1920000 and 1:480000, respectively
(Fig. 1D). It suggests that the prepared human exon-specific
antibodies have reliable specificity and sensitivity.
Tau exon-specific antibodies specifically recognized the
corresponding recombinant tau isoforms
To confirm whether prepared tau exon-specific antibodies could
recognize the tau isoforms which contain relevant exons in the
context of full-length protein, sequences encoding six human tau
isoforms were constructed (Fig. 2A). After purified with affinity
chromatography of nickel-NTA agarose, the recombinant proteins
were evaluated with SDS-PAGE. Clear single band was observed
in each preparation and the sizes were from 48 to 67 KD (Fig. 2B).
Western blot analyses with commercially tau-specific mAb Anti-
Tau1 showed specifically reactive band at the expected position in
each preparation of the eluted fraction (Fig. 2C).
Sixrecombinant tau proteinswereblottedontoPVDF membranes
and incubated with three tau exon-specific antibodies, respectively.
Western blots revealed that four isoforms containing exon-2 region
(Tau-381, -412, -410 and -441) reacted with Anti-tE2, two containing
exon-3 region (Tau-410 and -441) reacted with Anti-tE3 and three
containing exon 10 region (Tau-383, -412 and -441) reacted with
Anti-tE10. No cross-reaction was observed among three tested
antibodies in our experimental condition, indicating that the exon-
specific antibodies can recognize the relevant tau isoforms in the
context of full-length protein with a reliable specificity.
A CJD-related tau signal (Band-A) was repeatedly
identified in the CSF from the patients with probable CJD
To determine the reactive profiles of the prepared antibodies
with tau in CSF, human CSF samples collected from probable
Table 2. The main demological and clinical characteristics of
the patients in the groups of probable CJD and control.
Probable CJD Control
Number (n)
Male (n)
96
58
22
13
Female (n) 38 9
Median age at onset (y) (range) 60 (33–76) 58 (43–88)
Age at onset ,50 y (%) 13 (13.5%) 6 (27.3%)
Age at onset 50–70 y (%) 72 (75.0%) 13 (59.1%)
Age at onset .70 y (%) 11 (11.5%) 3 (13.6%)
Codon 129 genotype
Met-Met/total (%) 98.96 95.45
Met-Val/total (%) 1.04 4.54
Val-Val/total (%) 0 0
EEG
Positive/total (%)
56/59 (94.9%) 2/10 (20%)
14-3-3
Positive/total (%)
77/96 (80.2%) 10/22 (45.5%)
doi:10.1371/journal.pone.0011886.t002
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reacting with the three prepared tau exon-specific antibodies and
a commercial tau mAb Anti-Tau1. In general, three main
reactive bands were detected in human CSF specimen, with the
molecule weights of 65 KD (Band-A), 53 KD (Band-B) and
25 KD (Band-C), approximately (Fig. 3). Interestingly, the
profiles of tau in CSF differed among the reactions of various
tau antibodies, as well as between probable CJD and control
(Table 3). Band-A was observed only in the CSF samples of
probable CJD patients, but not in control samples (P,0.01).
Calculations of the positive numbers of Band-A in each reactive
group revealed that 38.5% samples (37/96) with Anti-tE2, 24%
samples (23/96) with Anti-tE10 and 7.3% samples (7/96) with
Anti-tE3 were positive, while none of the tested CSF samples
showed the positive Band-A when reacted with mAb Anti-Tau1.
Band-B was the most recognizable signal in each reactive group,
that more than 80% tested samples in the reactions with Anti-
tE2, Anti-tE3 and more than 70% in Anti-tE10, and roughly
20% samples with Anti-Tau1 showed positive Band-B. There
were no statistic differences in the positive rates between the
groups of probable CJD and control in the preparations of the
three tau exon-specific antibodies, despite that the control group
showed slight higher positive rates than the probable CJD.
Contrarily, the reactions with mAb Anti-Tau1 identified signifi-
cantly higher positive rate of Band-B in the control group (P,0.05).
Band-C was mostly detected in the reactions with Anti-tE10 and
Anti-Tau1,butinfrequentlyinthatwithAnti-tE2andnotwithAnti-
tE3. Only the reactions of Anti-tE10 revealed significantly higher
positive rate of Band-C in the control (P,0.05). Those data suggest
that the CSF tau profiles in Western blots are different between the
groups of probable CJD and non-CJD, in which Band-A that is
frequently recognized by Anti-tE2 and Anti-tE10 seems to be
related to CJD.
To determine the signal intensities of the tau-specific bands in
Western blots in distinguishing probable CJD and non-CJD, the
relative gray values of Band-B and -C in every blot of each CSF
sample were counted after equilibrated with the gray value of the
recombinant protein tau441 that was recognizable by all used tau
antibodies. The median relative gray values of each tau-specific
band reacted with each antibodies in the groups of probable CJD
and control were calculated (supplemental Table S1). No statistical
difference in the median relative gray values of Band-B or -C was
Figure 1. Preparations of tau exon-specific antigens and antibodies. (A) SDS-PAGE of the purified recombinant proteins GST-E2, GST-E3 and
GST-E10. The proteins were separated on a 12% SDS-PAGE and stained with 0.25% Coomassie brilliant blue. Various recombinant proteins are
indicated on the top. The relative molecular weights are shown on the left. (B) Identification of the recombinant proteins GST-E2, GST-E3 and GST-E10
by Western blots with GST specific antibody. Various recombinant proteins are indicated on the top. (C) Specificity assays of the purified human tau
exon-specific antibodies (Anti-tE2, Anti-tE3, and Anti-tE10) by Western blots. 2: GST-E2; 3: GST-E3; 10: GST-E10; G: GST. A commercial GST antibody is
used as the control. Various antibodies were indicated on the bottom. (D) Sensitivity assays of the purified human tau exon-specific antibodies (Anti-
tE2, Anti-tE3, and Anti-tE10) by an ELISA coated with the purified tau exon proteins. Left panel: Anti-tE2; Middle panel: Anti-tE3; Right panel: Anti-tE10.
X-axis shows the dilution of the antiserum and Y-axis shows the P/N values. The P/N value=2.1 is illustrated with a dotted-line.
doi:10.1371/journal.pone.0011886.g001
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regardless of the presence or absence of positive Band-A.
Presence of Band-A in CSF was relative to the positive 14-
3-3 in CSF and typical change in EEG
To determine the possible relationship between the appearances
of CSF tau-specific bands and the main demological and clinical
features, the positive rates of the tau bands were analyzed based on
several essential elements. No remarkable difference was found
when linked with gender and the onset ages (younger than 50 y,
between 50 and 70 y, elder than 70 y) of the patients (data not
shown). To address the correlation with protein 14-3-3 in CSF, all
118 patients who had 14-3-3 results were grouped into 14-3-3
positive (87 cases) and negative (31 cases). More numbers of Anti-
tE2-produced Band-A were detected in 14-3-3 positive group,
showing a statistic difference (P,0.05) compared with that of 14-3-
3 negative one (Table 4). Others, including Anti-tE3- and Anti-
tE10-produced Band-A, Band-B and Band-C, were not associated
with the emergence of 14-3-3 in CSF. To determine the relation
with the typical abnormality in EEG, 69 patients who received
EEG examinations were grouped into EEG positive (58 cases) and
negative (11 cases). More numbers of Anti-tE2-porduced Band-A
were found in EEG positive group, revealing a significant
difference (P,0.05) compared with that of EEG negative one
(Table 4). In line with the results of 14-3-3, the appearances of the
rest tau-specific bands had no relation with the typical abnormality
in EEG. It may emphasize again that emergences of Band-A in
CSF, especially Anti-tE2-produced Band-A, have comparable
significance as the presence of 14-3-3 in CSF and the typical
change in EEG for CJD.
Band-A was not detected in the CSF from six genetic
CJDs
Six CSF samples from various gCJD cases were also screened
for presences of tau signals by Western blots. Among them, two
cases (G200A and T188K fCJDs) showed positive 14-3-3 in CSF
and two others (P102L GSS and one G114V fCJD) were positive
in EEG. Incubations with tau exon-specific and full-length
antibodies identified predominant Band-B in all tested samples,
and less predominant Band-C in some cases. However, none of
them showed Band-A in their CSF (Fig. 4). It indicates that the tau
profiles in CSF of the genetic CJD are different from that of
sporadic CJD, possibly implying a distinct neurological pathogen-
esis of genetic CJD from sporadic CJD.
Discussion
We have successfully prepared three polyclonal antibodies
specifically against the peptides encoding from human tau exon-2,
exon-3 and exon-10, respectively. Although the molecular weights
of the peptides encoded by those three exons are similar, the
amino acid sequences of each exon peptide vary tremendously,
Figure 2. Immunoreactivities of the tau exon-specific antibodies with six recombinant human tau isoforms. (A) Schematic
representation of six human tau isoforms. (B) SDS-PAGE of the purifications of six expressed tau isoforms in E. coli. The lysates of bacteria and the
purified proteins were separated on a 12% gel and stained with 0.25% Coomassie brilliant blue. (C) Western blots of the prepared antibodies with six
recombinant human tau proteins. A commercial tau mAb Anti-Tau1 is used as the control. The blots with various antibodies are indicated on the
right. Different tau isoforms are shown on the top. The relative molecular weights are shown on the left.
doi:10.1371/journal.pone.0011886.g002
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bands have been detected in human CSF samples by Western
blots with three prepared tau polyclonal antibodies and one
commercial tau mAb and three bands are predominant. The
lengths of Band-A (65 KD) and -B (53 KD) are in the range of full-
length tau, likely representing two forms of full-length tau. Band-C
is much smaller (25 KD), possibly suggesting a form of the
truncated tau. Since the maturing process of tau protein in cells
undergoes post-translational modifications, i.e. phosphorylation
[19], the apparent molecular weights of tau in CSF are usually
different from the expected size [20]. The main phosphorylating
sites within tau are locate at the tubulin binding region, including
Ser-202/Thr-205, Ser-214/Ser-212, Thr-231/Ser-235 and Ser-
396/Ser-404 [15]. Those sites are relatively far from the three
inserted exons. Presumably, the prepared exon-specific antibodies
may recognize both phosphorylated and un-phosphorylated tau
proteins.
A tau band (Band-A) emerges as a specific band in CSF samples
of probable CJD patients, especially when reacted with the
antibodies against the tau exon-2 and -10, indicating a disease-
(even CJD-) relative manner. It highlights the possibility that tau
Band-A in CSF might be another useful biomarker for CJD
diagnosis. Release of tau protein into CSF is a normal metabolic
process [21], however, increase of tau protein in CSF is also
Figure 3. The reactive profiles of tau in CSF samples from probable CJD patient and control in Western blots. Lane 1: recombinant
human tau protein Tau441 as a marker; Lane 2–9: individual CSF samples. The panels from top to bottom are the reactions with Anti-tE2, Anti-tE3,
Anti-tE10 and Anti-Tau1, indicated in the middle. Left panels are CSF samples from probable and right panels are the ones from non-CJD. Tau-specific
reactive bands (Band-A, -B and -C) are marked by arrows. The relative molecular weights are shown on the left.
doi:10.1371/journal.pone.0011886.g003
Table 3. Comparison of the positive rates of the tau-specific
bands with different antibodies between the groups of
probable CJD and control in Western blots.
Antibody Band Probable CJD(n) Control(n) p
Anti-tE2 Band-A
* 38.5% (37/96) 0% (0/22) 0.0004
Band-B 83.3% (80/96) 95.5% (21/22) 0.19
Band-C 4.2% (4/96) 13.6% (3/22) 0.119
Anti-tE3 Band-A 7.3% (7/96) 0% (0/22) 0.345
Band-B 85.4% (82/96) 100% (22/22) 0.069
Band-C 0% (0/96) 0% (0/22) -
Anti-tE10 Band-A
* 24.0% (23/96) 0% (0/22) 0.007
Band-B 70.8% (68/96) 90.9% (20/22) 0.051
Band-C
1 70.8% (68/96) 100% (22/22) 0.004
Anti-Tau1 Band-A 0% (0/96) 0% (0/22) -
Band-B
1 20.8% (20/96) 77.3% (17/22) 0.0000003
Band-C 80.2% (77/96) 81.8% (18/22) 1
*significantly higher than control group (P,0.01).
1significantly lower than control group (P,0.01).
doi:10.1371/journal.pone.0011886.t003
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tau can be detected in a serial of neurological diseases, i.e. AD,
frontotemporal dementia, Lewy body dementia and vascular
dementia [11]. Numerous literatures have addressed the remark-
ably increased CSF tau in CJD patients by ELISA, proposed as
one of the diagnostic criteria for CJD [22]. Whether the increased
tau in CSF of CJD patients is due to the appearance of tau Band-A
is unclear. Nevertheless, our data here illustrate a distinct profile of
CSF tau in CJD patients, suggesting that different tau components
are released from brains into CSF during CJD pathogenesis.
In line with previous tau ELISA assays [14], the appearances of
Band-A of tau in CSF showed no linkage with the onset age and
gender of the tested probable CJD cases. Well correlations of
positive tau Band-A with positive 14-3-3 in CSF, and with typical
abnormality in EEG have been observed. Presence of 14-3-3 in
CSF is usually believed as a result of neuronal damage or death
[23]. EEG exhibits special changes in sporadic CJD, ranging from
nonspecific findings such as diffuse slowing and frontal rhythmic
delta activity (FIRDA) in early stages to disease-typical periodic
sharp wave complexes (PSWC) in the middle stage and a reactive
coma traces or even alpha coma in late stage [24]. Both positive
14-3-3 in CSF and PSWC in EEG are included in the World
Health Organization diagnostic classification criteria of CJD [6].
Significant correlations among positive tau Band-A, positive 14-3-
3 in CSF and typical abnormality in EEG emphasize again that
Band-A of tau in Western blots with exon-specific antibodies is a
Table 4. Comparison of the positive rates of the tau-specific bands in different Western blots between different groups.
Antibody Band 14-3-3 (+) 14-3-3 (2) p EEG (+) EEG (2)P
Anti-tE2 Band-A
* 36.8% (32/87) 16.1% (5/31) 0.030 36.2% (21/58) 0% (0/11) 0.0145
Band-B 83.9% (73/87) 90.3% (28/31) 0.553 86.2% (50/58) 100% (11/11) 0.338
Band-C 4.6% (4/87) 9.7% (3/31) 0.377 5.2% (3/58) 18.2% (2/11) 0.177
Anti-tE3 Band-A 6.9% (6/87) 3.2% (1/31) 0.674 1.7% (1/58) 0% (0/11) 1
Band-B 87.4% (76/87) 90.3% (28/31) 1.000 86.2% (50/58) 100% (11/11) 0.338
Band-C 0% (0/87) 0% (0/31) - 0% (0/58) 0% (0/11) -
Anti-tE10 Band-A 20.7% (18/87) 16.1% (5/31) 0.582 25.9% (15/58) 9.1% (1/11) 0.436
Band-B 73.6% (64/87) 77.4% (24/31) 0.672 75.7% (44/58) 72.7% (8/11) 1
Band-C 74.7% (65/87) 80.6% (25/31) 0.505 70.0% (40/58) 90.9% (10/11) 0.268
Anti-Tau1 Band-A 0% (0/87) 0% (0/31) - 0% (0/58) 0% (0/11) -
Band-B 26.4% (23/87) 45.2% (14/31) 0.054 24.1% (14/58) 54.5% (6/11) 0.067
Band-C 79.3% (69/87) 83.9% (26/31) 0.582 84.5% (49/58) 81.8% (9/11) 1
*statistically higher than the groups of negative 14-3-3 and negative EEG, respectively (P,0.05).
doi:10.1371/journal.pone.0011886.t004
Figure 4. The reactive profiles of tau in CSF samples from six gCJD patients in Western blots. Various gCJD cases are indicated on the
bottom. The reactions with Anti-tE2, Anti-tE3, Anti-E10 and Anti-Tau1 are shown on the top. Tau-specific reactive bands (Band-A, -B and -C) are
marked by arrows. The relative molecular weights are shown on the left.
doi:10.1371/journal.pone.0011886.g004
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PSWC in EEG are not CJD-exclusive [24]. In contrast, appear-
ance of the fraction of Band-A of tau seems to be more CJD-
specific. More cohort studies, especially covering the CSF samples
from definitely diagnosed CJD patients, will define its significance
in the diagnosis for sporadic CJD.
CSF samples from six definitely diagnosed gCJD cases in this
study do not reveal Band-A in Western blots. Certainly, the sample
size is too small to draw any meaningful conclusion, but it raised a
question of whether the detection of Band-A is suitable for gCJD.
Unlike the roles in sporadic CJD, measurements of CSF 14-3-3
and EEG usually have much less significance in the diagnosis for
human gCJD [22,24]. Increased CSF tau level in gCJD is rarely
observed [22]. It may reflect a complicated pathogenic mechanism
of human TSE. The potential effectiveness of polymorphism at
codon 129 on the appearance of tau Band-A remains unsettled, as
only one case of probable CJD shows Mel/Val heterozygous,
which is common feature for Han Chinese [25].
The apparent molecular weights of recombinant tau isoforms in
SDS-PAGE usually differ from expected molecular weights,
ranging from 48 to 67 KD. This may be related to the unusual
amino acids constitutions of the inserts and the extended
configuration of tau [26,27]. The six recombinant tau isoforms
expressed in this study have also revealed the difference between
the apparent and expected molecular weights, e.g. recombinant
Tau383 and Tau412 showing markedly small apparent molecular
weights. Since more factors may affect the phenotypes of tau
proteins, e.g. posttranslational modification, proteolysis and
truncated expression, the tau isoforms in bio-samples are even
harder to be defined in SDS-PAGE based on the apparent
molecular weights. Therefore, the immunoreactivities of tau
proteins with the antibodies against the different inserted exons
may supply an alternative methodology to estimate the tau
components in samples.
Based on the immunoreactivity, large proportion of Band-A is
the tau peptides containing exon-2 and exon-10. Some of them
contain only exon-2 or exon-10, and a few contain exon-2 and
exon-3. This observation indicates that a single tau reactive band
in Western blot may compose of several tau isoforms that migrate
at the same position in SDS-PAGE. Similar phenomenon has been
observed in Band-B and -C. It highlights again the difficulty in
distinguishing tau isoforms with their apparent molecular weights.
Under our experimental situation the commercial mAb Anti-Tau1
failed to recognize Band-A and the reason is not clear. Anti-Tau1
recognizes the internal epitopes (amino acid 189–207, according to
the numbering of the longest isoform) in the intact tau protein, and
our results confirmed that it can react with all recombinant tau
isoforms in Western blots. Previous study has revealed that Anti-
Tau1 fails to recognize the tau proteins phosphorylated at Ser-195,
Ser-198, Ser-199 and/or Ser-202 [28]. Hence, we speculate that
the fraction of Band-A in CSF might be a group of phosphorylated
tau proteins that are wholly or partially modified at those sites.
In summary, we raised the human tau exon-specific antibodies
against the peptides encoded by exon-2, -3 or -10. A CJD-related
band has been detected in CSF samples of probable CJD patients.
The methodology described here could be used as another tool for
CJD diagnosis, using relatively easily-collected human CSF
specimen, especially for CJD diagnosis in the countries like China
where the brain postmortem is rarely performed because of the
tradition.
Supporting Information
Table S1 The signal intensities of various tau-specific bands in
the groups of probable CJD and control in Western blots.
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Figure S1 Mass spectrometry assays of the purified recombinant
GST-tau exon proteins. X-axis represents the molecular weights
and Y-axis represents the signal intensity. Various recombinant
proteins are indicated on the top.
Found at: doi:10.1371/journal.pone.0011886.s002 (0.24 MB TIF)
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